SCHEMBL1475635

SCHEMBL1475635

COc1ccc(CCNC(=O)c2cc(-c3ccco3)on2)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.80
SMN1; SMN2 Q16637 9/20 0.77
MAPT P10636 6/20 0.77
LMNA P02545 3/20 0.77
HTT P42858 3/20 0.77
NPC1 O15118 9/20 0.76
RAB9A P51151 9/20 0.76
KMT2A Q03164 3/20 0.67
MEN1 O00255 2/20 0.67
HPGD P15428 5/20 0.66
GAA P10253 2/20 0.66
TP53 P04637 2/20 0.66
UBE2I P63279 1/20 0.60
CACNA1B Q00975 1/20 0.60
APBA1 Q02410 1/20 0.60
CTDSP1 Q9GZU7 1/20 0.60
SAE1 Q9UBE0 1/20 0.60
UBA2 Q9UBT2 1/20 0.60
MAPK1 P28482 1/20 0.58
THRB P10828 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1475213 0.89 ALDH1A1 (0.74) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL1474708 0.88 ALDH1A1 (0.74) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL1476447 0.88 ALDH1A1 (0.80) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL1475514 0.87 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL1474866 0.86 ALDH1A1 (0.82) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL1474855 0.86 NPC1 (1.00) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL1474280 0.86 ALDH1A1 (0.72) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL1475563 0.85 ALDH1A1 (0.80) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL1474503 0.85 ALDH1A1 (0.80) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL1474843 0.85 NPC1 (0.80) ALDH1A1SMN1; SMN2MAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 ALDH1A1 706/4885SMN1; SMN2 3980/4885MAPT 2497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.